Edition:
India

People: Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

19.25USD
2:29am IST
Change (% chg)

$0.72 (+3.89%)
Prev Close
$18.53
Open
$18.60
Day's High
$19.80
Day's Low
$18.50
Volume
24,491
Avg. Vol
27,651
52-wk High
$20.01
52-wk Low
$5.65

Pereira, Brian 

Dr. Brian J. G. Pereira M.D. serves as Independent Director of the Company. Dr. Pereira has served as a member of our Board since February 2019. Dr. Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. He has been President & CEO of Visterra, Inc. since 2013 and continues to serve in this role after the acquisition by Otsuka in August 2018. He previously served as President & CEO of AMAG Pharmaceuticals where he raised four financing rounds at increasing valuations and built the clinical development, manufacturing, supply-chain and commercial infrastructure for Feraheme. Prior to AMAG Pharmaceuticals, he held senior roles at Tufts Medical Center, including President and CEO of a Tufts Medical Center Physician Organization and interim COO. Brian is Executive Chairman of the Board of Directors of Abeona Inc., and Chairman of the Board of Directors of Africa Healthcare Network. He serves on the Board of Cullinan Pearl Corp and Visterra, Inc, and has previously served on the Board of several private and public companies. He serves on the Board of Directors of the America India Foundation and Board of Advisors of Life Sciences Cares. He was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles. He received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute and MBA from Kellogg School of Management at Northwestern University. We believe that Dr. Pereira is qualified to serve on our Board because of his extensive experience in and knowledge of our industry.

Basic Compensation

Total Annual Compensation, USD 47,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 47,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --